Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

Stopped early · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving internal radiation therapy using a special radiation therapy device may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well internal radiation therapy after lumpectomy works in treating women with ductal carcinoma in situ.

Key facts

Study ID

NCT00290654

Run by

Masonic Cancer Center, University of Minnesota

People needed

45

Starts

2002-12-01

Expected to finish

2013-03-01

Last updated by the study team

2017-12-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Ductal carcinoma in situ (DCIS) confirmed by excisional or needle biopsy
• Size: < 3 cm on mammogram
• Unicentric disease
• Ability to place MammoSite device at time of lumpectomy or within 4 weeks of lumpectomy
• Patient Age: ≥ 18 years, no upper limit
• Life expectancy > 5 years

You may not qualify if…

• Prior history of cancer other than basal or squamous cell skin cancer or in situ cancer of the cervix
• Pregnant or breast feeding
• Multicentric disease
• Diagnosis of collagen vascular diseases, such as systemic lupus erythematosis, scleroderma, or dermatomyositis

Where it is running

• Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.